# 05. Financial Applications

This document details the financial models and actuarial formulas used to translate clinical risk predictions into financial valuation and underwriting decisions.

## 1. Insurance Actuarial Premium Pricing

Traditional premiums are calculated using historical claims data. HealthRisk AI enhances this by embedding the clinical stacking ensemble’s **30-day readmission probability ($P_{readmit}$)** directly as a risk multiplier:

$$\text{Premium}_{adjusted} = \text{Baseline Premium} \times (1 + \alpha \cdot P_{readmit})$$

### Incurred But Not Reported (IBNR) Claim Reserves
To maintain solvency, insurers must hold reserves for claims that have occurred but have not yet been reported. We implement the **Chain Ladder Method** and the **Bornhuetter-Ferguson Method** on claims triangles:
- **Chain Ladder**: Estimates ultimate claims by computing Cumulative Development Factors (CDF) from age-to-age link ratios.
- **Bornhuetter-Ferguson**: Blends the Chain Ladder estimate with a priori loss ratios, providing a stable reserve model for volatile or recent accident years.

## 2. Hospital Credit Risk & Municipal Bonds

Hospitals issue municipal bonds to finance capital expenditures. Standard credit rating agencies (Moody's, S&P) evaluate them using purely financial metrics (operating margin, debt service coverage ratio).
HealthRisk AI implements an **Enhanced Credit Scorecard** that includes clinical quality indicators:

$$\text{Credit Score} = f(\text{Operating Margin}, \text{DSCR}) - \beta \cdot \text{Readmission Rate} + \gamma \cdot \text{CMS Stars}$$

### Default Probability (PD) Model
- High readmission rates reflect poor quality of care, which results in financial penalties under CMS Medicare value-based purchasing rules.
- By utilizing survival models (DeepSurv) to predict time-to-debt-covenant-breach, the PD model acts as an early warning system, predicting rating downgrades 6 to 12 months ahead of traditional financial audits.

## 3. Pharmaceutical Portfolio rNPV

Drug pipeline assets are valued using the **Risk-Adjusted Net Present Value (rNPV)** method, which adjusts projected cash flows by transition probabilities across clinical phases:

$$\text{rNPV} = \sum_{t=1}^{N} \frac{\text{Cash Flow}_t \times P_{success}}{(1 + r)^t} - \text{R\&D Cost}$$

- **Monte Carlo Simulations**: Runs thousands of trials varying peak sales, patent runways, and launch delays.
- **Clinical Alpha Portfolio Optimization**: Integrates real-time trial enrollment velocity and FDA safety events to rebalance biopharma equity weights, improving the portfolio's Sharpe ratio.
